Phase ib randomized, Double-blinded, Placebo- Controlled, Dose escalation study of polyphenon e in patients with barrett's esophagus

Cancer Prevention Research

Volumn 8, Issue 12, 2015, Pages 1131-1137

  Joe, Andrew K ^a   Schnoll Sussman, Felice ^b   Bresalier, Robert S ^c   Abrams, Julian A ^a   Hibshoosh, Hanina ^a   Cheung, Ken ^a   Friedman, Richard A ^a   S yang, Chung ^d   Milne, Ginger L ^e   Liu, Diane D ^c   Lee, J Jack ^c   Abdul, Kazeem ^a   Bigg, Michelle ^b   Foreman, Jessica ^c   Su, Tao ^a   Wang, Xiaomei ^a   Ahmed, Aqeel ^a   Neugut, Alfred I ^a   Akpa, Esther ^c   Lippman, Scott M ^f   Perloff, Marjorie ^g   Brown, Powel H ^c   Lightdale, Charles J ^a   more..

^a Department of Medicine   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CATECHIN; CREATININE; LACTATE DEHYDROGENASE; PLACEBO; POLYPHENON E; TRIACYLGLYCEROL LIPASE; EPIGALLOCATECHIN GALLATE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPIC BIOPSY; ERUCTATION; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; LACTATE DEHYDROGENASE BLOOD LEVEL; LOSS OF ENERGY; MALE; MULTICENTER STUDY; NAUSEA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH DISCOMFORT; STOMACH PAIN; TASTE DISORDER; UPPER RESPIRATORY TRACT INFECTION; VERY ELDERLY; ANALOGS AND DERIVATIVES; BIOPSY; CLINICAL TRIAL; DOSE RESPONSE; ESOPHAGOSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; PHYTOTHERAPY; PROCEDURES;

AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOPSY; CATECHIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESOPHAGOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY;

EID: 84951952332     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0274-T     Document Type: Article

References (29)

1. Ju J, Lu G, Lambert JD, Yang CS. Inhibition of carcinogenesis by tea constituents. Semin Cancer Biol 2007;17:395-402.
2. Kuroda Y, Hara Y. Antimutagenic and anticarcinogenic activity of tea polyphenols. Mutat Res 1999;436:69-97.
3. Borgovan T, Bellistri JP, Slack KN, Kopelovich L, Desai M, Joe AK. Inhibition of BCL2 expression and activity increases H460 sensitivity to the growth inhibitory effects of polyphenon E. J Exp Ther Oncol 2009;8:129-44.
4. Yang CS, Lambert JD, Ju J, Lu G, Sang S. Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol 2007;224:265-73.
5. Song S, Krishnan K, Liu K, Bresalier RS. Polyphenon E inhibits the growth of human Barrett's and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression. Clin Cancer Res 2009;15:622-31.
6. Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM, Namkoong SE, et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 2003;12:383-90.
7. Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, et al. Green tea extracts for the prevention of metachronous colorectal adenomas: A pilot study. Cancer Epidemiol Biomarkers Prev 2008;17:3020-5.
8. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40.
9. Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013;119:363-70.
10. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, et al. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res 2012;5:1144-54.
11. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf, August 9, 2006.
12. Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin- 3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 2002;11:1025-32.
13. Mohebati A, Milne GL, Zhou XK, Duffield-Lillico AJ, Boyle JO, Knutson A, et al. Effect of zileuton and celecoxib on urinary LTE4 and PGE-Mlevels in smokers. Cancer Prev Res 2013;6:646-55.
14. The University of Texas, MD Anderson Cancer Center RPPA Core Facility - Functional Proteomics. Available from: http://www.mdanderson.org/education-and-research/resources-for-professionals/scientific-resources/corefacilities-and-services/functional-proteomics-rppa-core/index.html, 2015.
15. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000;56:1177-82.
16. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
17. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate; a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995:57:289-300.
19. American Gastroenterological Association Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140:1084-91.
20. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003;9:3312-9.
21. Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, et al. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: Evaluation of potential chemopreventive activities. Cancer Prev Res 2012;5:290-8.
22. Jimenez P, Piazuelo E, Cebrian C, Ortego J, Strunk M, García-Gonzalez MA, et al. Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. Aliment Pharmacol Ther 2010;31:440-51.
23. Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol Med Rep 2008;1: 355-61.
24. Hamberg M, Samuelsson B. The structure of the major urinary metabolite of prostaglandin E2 in man. J Am Chem Soc 1969;91:2177-8.
25. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ II. Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 1988;319:689-98.
26. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase- specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334:266-75.
27. Duffield-Lillico AJ, Boyle JO, Zhou XK, Ghosh A, Butala GS, Subbaramaiah K, et al. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: Evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res 2009;2: 322-9.
28. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res 2013;6:428-36.
29. Garcia FA, Cornelison T, Nuno T, Greenspan DL, Byron JW, Hsu CH, et al. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia. Gynecol Oncol 2014;132:377-82.